Enhancement of Tamoxifen-Induced E-Cadherin Function by Ca2+ Channel Antagonists in Human Breast Cancer Mcf7/6 Cells by Charlier, Corinne et al.
Published in: European Journal of Pharmacology (1996), vol. 317, pp. 413-416 
Status: Postprint (Author’s version) 
 
Enhancement of tamoxifen-induced E-cadherin function by Ca2+ channel 
antagonists in human breast cancer MCF7/6 cells 
Corinne Charlier a,b, Eric Bruyneelc, Chantai Lechanteura,b, Marc Brackec, Marc Mareelc, Vincent Castronovoa,* 
aMetastasis Research Laboratory, University of Liège, Liège, Belgium 
bClinical Chemistry Department, University of Liège, Liège, Belgium 
cLaboratory of Experimental Cancerology, University of Gent, Gent, Belgium 
Abstract 
Despite its intensive use in adjuvant breast cancer therapy for more than 30 years, the exact mechanisms of 
action of tamoxifen have not yet been fully characterized. Tamoxifen was recently shown to restore the E-
cadherin function of human breast cancer MCF7/6 cells and to suppress their invasive phenotype. Because 
tamoxifen interacts with targets implicated in Ca2+ homeostasis, we explored the possibility that the restoration 
of E-cadherin function in MCF7/6 cells induced by this drug could be affected by Ca2+ modulators. Two 
different Ca2+ channel antagonists (verapamil and nifedipine) potentiated the effect of tamoxifen on E-cadherin 
function, as evaluated with a fast cell aggregation assay. These molecules decreased the tamoxifen concentration 
needed to restore the E-cadherin function from 10-6 M to 10-7 M. When incubated with a Ca2+ channel agonist, 
Bay K8644 (methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoro-methylphenyl)-pyridine-5-carboxylate), the 
effect of tamoxifen on E-cadherin function was completely abolished. These results demonstrate that the 
restoration of the E-cadherin function induced by tamoxifen depends, at least in part, on a Ca2+ pathway, and 
support the evidence of an effect of tamoxifen on Ca2+-dependent mechanisms. Our data also suggest that Ca2+ 
channel modulators could make it possible to decrease the dose of tamoxifen administered to patients without 
reducing the therapeutic effects. 
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1. INTRODUCTION 
Tamoxifen is the first molecule considered as a breast cancer prevention agent. Although this antiestrogen has 
been successfully used for more than 30 years in adjuvant therapy of advanced breast cancer, its exact 
mechanisms of action remain unclear (Coezy et al., 1982; Osborne et al., 1983; Wiseman et al., 1993). There is 
now clinical and experimental evidence suggesting that tamoxifen acts through several mechanisms, some of 
which are independent of its interactions with estrogen receptors (Antoniotti et al., 1992; Charlier et al., 1994; 
Jeng et al., 1993). Tamoxifen has been reported to have a therapeutic effect on patients with estrogen receptor 
negative breast cancer, while it is sometimes ineffective in cancers with estrogen receptor positive cells (Baker et 
al., 1992; Fisher et al., 1989; Fuqua et al., 1993). The proliferation of MDA-MB435 cells, a cell line which does 
not express estrogen receptors, is inhibited by tamoxifen (Charlier et al., 1995). The identification of the exact 
mechanisms of action of tamoxifen is necessary to assure a safe and appropriate administration of the drug both 
to breast cancer patients as adjuvant therapy, and to high risk women as a preventive agent. Because the 
recommended pharmacological doses are associated with undesirable side effects, any way that would decrease 
the required doses of tamoxifen without altering its therapeutic or preventive effects would be most welcome. 
Recently, we showed that tamoxifen (10-6 M) restored the function of the expressed but inactive cell-cell 
adhesion E-cadherin/catenin complex in MCF7/6 human breast cancer cells (Bracke et al., 1994).                            
E-cadherin/catenin is a tumor suppressor complex whose alterations of function or expression are frequent 
features of invasive cells. At a similar concentration, tamoxifen suppressed the invasive phenotype of MCF7/6 
cells in an in vitro invasion assay. These observations suggest that the therapeutic activity of tamoxifen could be 
linked, at least in part, to E-cadherin function (Bracke et al., 1994). Ca2+ participates in the regulation of the E-
cadherin/catenin complex. Furthermore, there are several studies indicating that Ca2+ dependent pathways could 
be involved in the mechanisms of action of tamoxifen (Castoria et al., 1988; Strobl et al., 1994). These data 
prompted us to test the hypothesis that the restoration of the E-cadherin/catenin complex function induced by 
tamoxifen could be modulated by Ca2+ modulators. This paper reports our experiments with voltage-gated Ca2+ 
channel antagonists, verapamil and nifedipine, and agonist, BayK8644 (methyl-1,4-dihydro-2,6-dimethyl-3-
nitro-4-(2-trifluoromethylphenyl)-pyridine-5-carboxylate). 
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2. MATERIALS AND METHODS 
2.1. Cells 
Human breast cancer cells MCF7/6 (Soule et al., 1973) were obtained from Dr H. Rochefort (Unité 
d'Endocrinologie Cellulaire et Moléculaire, Montpellier, France) and maintained in Dulbecco's modified Eagle's 
medium/Ham F12 50:50 (Flow, Irvine, Scotland, UK) supplemented with 0.05% glutamine (w/v), 250 IU/ml 
penicillin, 100 µg/ml streptomycin, and 10% fetal calf serum. Cells were incubated in a 5% CO2 incubator, under 
a water-saturated atmosphere. The medium was replaced every 3 days. 
2.2. Chemicals and antibodies 
Tamoxifen was kindly provided by Besins-Iscovesco (Paris, France). Verapamil and nifedipine were purchased 
from Sigma Chemical Co. (St. Louis, MO, USA). Stock solutions of tamoxifen and nifedipine were prepared in 
ethanol, while stock solutions of verapamil were maintained in culture medium and kept in the dark. Bay K8644 
was purchased from ICN (Costa Mesa, CA, USA) and a stock solution was prepared in dimethyl sulfoxyde 
(DMSO) and kept frozen. The monoclonal anti-E-cadherin antibody MB2 was a gift from Dr. Y. Shimoyama 
(Pathology Division, National Cancer Research Institute, Tokyo, Japan). 
2.3. Fast aggregation assay 
The fast aggregation assay was described previously (Bracke et al., 1994). Briefly, a cell suspension prepared 
under E-cadherin and Ca2+ saving conditions was incubated widi various concentrations of tamoxifen alone or in 
combination with various concentrations of Ca2+ channel antagonists. The number of particles in the suspension 
was measured with a Coulter Counter ZM (Coulter Counter Electronics, Luton, UK) at the start of the incubation 
(N0) and after 30 min (N30). All the experiments were done at least three times, in duplicate, and all the tests 
were simultaneously done in the presence of the MB2 antibody in control experiments. 
Fig. 1: Fast MCF7/6 cell aggregation expressed as 1 — N30/N0, where N0 is the initial number of particles in 
suspension and N10 is the number after 30 min. Data for co-incubation of the cells with tamoxifen and verapamil 
(A) or nifedipine (B), or incubation with the Ca2+ channel antagonists alone are presented. The induction was 
significant with verapamil (P < 0.01) and nifedipine (P< 0.0S) according to the Student's t-test. The incubation 
of MCF7/6 cells with tamoxifen 0.1 µM in combination with verapamil 10 µM restored the results of the fast 
aggregation assay to the same value as the aggregation obtained with 1 µM of tamoxifen alone. Simultaneous 
incubation with anti-cadherin monoclonal MB2 antibody abolished the fast aggregation. Each experiment was 
performed in duplicate and was reproduced at least three times. 
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3. RESULTS 
To evaluate the effects of voltage-gated Ca2+ channel antagonists on tamoxifen induction of E-cadherin/catenin 
function, we used the fast aggregation assay previously described (Bracke et al., 1994). As shown in Fig. 1, 
tamoxifen at 1 µM - but not at 0.1 µM - stimulated the aggregation of MCF7/6 cells. Anti-E-cadherin 
monoclonal antibody MB2 suppressed the induced aggregation, suggesting that tamoxifen restores the E-
cadherin function. Addition of the voltage-gated Ca2+ channel antagonists, verapamil and nifedipine, to MCF7/6 
cells in the presence of 0.1 µM tamoxifen led to a partial or complete restoration of the aggregation. In the 
presence of verapamil, tamoxifen was able to restore the aggregation function at a concentration of 10-7 M, 
which was 10 times lower than the minimal one needed when the antiestrogen was used alone. This effect was 
less pronounced with nifedipine than with verapamil. The effect observed with verapamil and nifedipine was 
dose dependent, reaching a plateau at 10 µM, and was inhibited by the presence of monoclonal antibody MB2 
(Fig. 1). When added alone at various concentrations, the Ca2+ channel antagonists had no effect on MCF7/6 
aggregation (Fig. 1). 
Cell aggregation induced by tamoxifen and Ca2+ channel antagonists increased rapidly, with a maximum activity 
observed after 10 min (data not shown). 
We also tested a Ca2+ channel agonist, Bay K8644, in the same fast aggregation assay. Bay K8644 is a 
dihydropyridine which opens the Ca2+ channel. The drug completely abolished the tamoxifen induction of E-
cadherin/catenin complex function (Fig. 2). The effect of Bay K8644 was dose dependent and started at a 
concentration of 100 nM. Used alone, this drug had no effect on the aggregation of MCF7/6 cells. 
Fig. 2: Fast MCF7/6 cell aggregation expressed as 1 - N30/N0 in the presence of the Ca2+ channel agonist Bay 
K8644 alone or in combination with tamoxifen. Bay K8644 abolished the effect of the optimal concentration of 
tamoxifen. This effect was dose dependent and started at a concentration of 100 nM (P < 0.01). Each experiment 
was performed in duplicate and was reproduced at least three times. 
 
4. DISCUSSION 
The mechanisms of action of tamoxifen as a therapeutic and potentially preventive agent in human breast cancer 
are still under intense investigations. Recendy, we have demonstrated that tamoxifen restores, at pharmacological 
concentrations, the function of the invasion suppressor complex E-cadherin/catenin in human breast cancer cells 
MCF7/6 (Bracke et al., 1994). This activity could participate in the therapeutic benefit associated with tamoxifen 
uptake. The possibility that Ca2+-dependent pathways could be involved was considered because (a) a recent 
study indicated that voltage-gated Ca2+ channel antagonists potentiated the antiproliferative effects of tamoxifen 
(Gupta et al., 1994), (b) tamoxifen can interact with several Ca2+ control elements including calmodulin (Strobl 
et al., 1994), and (c) E-cadherin/catenin functions are Ca2+ dependent. In this work, we have demonstrated that 
the voltage-gated Ca2+ channel antagonist, verapamil, and to a lesser extent, nifedipine, potentiated the effects of 
tamoxifen on E-cadherin/catenin functions. The modulation of cytoplasmic Ca2+ concentration by these drugs 
could affect E-cadherin/catenin complex function, since Ca2+ seems to play a role in stabilizing interactions 
between successive cadherin domains (Shapiro et al., 1995). Indeed, verapamil caused a 10-fold decrease in the 
concentration of tamoxifen needed to restore the aggregation of MCF7/6 cells. Our study provides the first 
evidence that voltage-gated Ca2+ channel antagonists are able to significantly reduce the dose of tamoxifen 
without altering its pharmacological action, i.e. the restoration of a tumor suppressor gene function. Our finding 
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could have important clinical implications. The combination of tamoxifen with Ca2+ homeostasis modulators 
could indeed permit the dose of tamoxifen required to reach a protective effect to be decreased and thereby 
reduce the incidence of its side effects. 
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